Oncology

+

Blue Bees Therapeutics

Lilly Moran, 21 January, 2025, 0

Blue Bees Therapeutics First in a new class of cancer immunotherapies

+

MiWEndo Solutions

Lilly Moran, 21 January, 2025, 0

MiWEndo Solutions Reducing missed colorectal cancer diagnoses with cutting-edge microwave imaging technology

+

ReACT Therapeutics

Émile Roussel, 25 November, 2024, 0

ReACT Therapeutics Breaking the Cancer Resistance Barrier Cancer therapeutics In vitro, proof of concept France 950.000€ Status Approved IP Type...

+

NeoTargets

Lilly Moran, 13 November, 2024, 0

NeoTargets We oﬀer a unique approach to signiﬁcantly de-risk drug discovery through several proprietary methodologies Cancer Therapeutics In vitro, proof...

+

Nanobots Therapeutics

Heidi Rohwer, 14 October, 2024, 0

Nanobots Therapeutics Unique therapeutic entities that penetrate tissues with superior efficacy, enhancing drug accumulation in target cells Cancer therapeutics In...

+

Kairos Discovery

Heidi Rohwer, 5 June, 2024, 0

Kairos Discovery Kairos Discovery develops small molecules targeting protein kinases to treat cancer Cancer therapeutics Prototyping, preclinical France 1.500.000€ Status...

+

Aptadel Therapeutics

Heidi Rohwer, 15 May, 2024, 0

Aptadel Therapeutics A biotech company developing RNA technologies for the treatment of childhood cancer Cancer therapeutics Prototyping, preclinical Spain 1.500.000€...

+

Theraonco

Heidi Rohwer, 16 February, 2024, 0

Theraonco Theraonco enhances efficacity of wide range of payload agents and reduces their side effects Cancer therapeutics Prototyping, preclinical France...

+

Hemerion Therapeutics

Heidi Rohwer, 8 February, 2024, 0

Hemerion Therapeutics Advancing cancer therapies. At the speed of light. Cancer therapeutics Development, market readiness, clinical trial France 2.000.000€ Status...

+

Inti Biotech

Heidi Rohwer, 29 January, 2024, 0

Inti Biotech Explore the next frontier in advanced cancer therapy: Microgravity Cancer therapeutics Prototyping, preclinical Canada 3.000.000$ Status - IP...